Article
Author(s):
Value-based contracts may also improve patient outcomes by increasing access to innovative medicines and supporting appropriate use.
Commercially insured individuals with health plans with value-based contracts for diabetes, high cholesterol, and HIV medicines had average co-pays that were 28% lower for those prescription medications compared with people on other plans, according to a report from the Pharmaceutical Research and Manufacturers of America (PhRMA).
Payers are exploring new contracts that connect reimbursement for medicines to the value for individual patients. Types of potential value-based contracts include performance-, outcomes-, indication-, and regimen-based contracts, among others.
“Results-based or value-based contracts can reduce healthcare system costs and can make medicines more affordable and accessible for patients,” Stephen J. Ubl, president and CEO of PhRMA, said in a press release. “The healthcare market is starting to move in this direction, but we need public policy reforms that allow greater flexibility for innovative payment arrangements that lower out-of-pocket costs and enable patients to access the right treatments the first time.”
For more information, please visit AJMC.com.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.